Ernest A Kopecky
Overview
Explore the profile of Ernest A Kopecky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
915
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kopecky E, Vaughn B, Lagasse S, OConnor M
Drugs Aging
. 2017 Jun;
34(8):603-613.
PMID: 28600725
Trial Design: This was a phase III, randomized withdrawal, double-blind, placebo-controlled, enriched enrollment, parallel-group, multicenter study intended to demonstrate the safety, tolerability, and analgesic efficacy of oxycodone DETERx (Xtampza™ ER)...
12.
Smith S, Jones J, Katz N, Roland C, Setnik B, Trudeau J, et al.
J Pain
. 2017 May;
18(11):1287-1294.
PMID: 28479207
Perspective: Identifying a medication's abuse potential requires assessing inappropriate medication use events in clinical trials on the basis of a standardized event classification system. The strengths and limitations of the...
13.
Smith S, Dworkin R, Turk D, Baron R, Polydefkis M, Tracey I, et al.
J Pain
. 2017 Mar;
18(7):757-777.
PMID: 28254585
Perspective: The applicability of sensory testing, skin biopsy, and brain imaging as diagnostic, prognostic, predictive, and pharmacodynamic biomarkers for use in analgesic treatment trials is considered. Evidence in support of...
14.
Gudin J, Kopecky E, Fleming A
Pain Med
. 2017 Jan;
18(5):992-994.
PMID: 28074029
No abstract available.
15.
Kopecky E, Fleming A, Levy-Cooperman N, OConnor M, Sellers E
J Clin Pharmacol
. 2016 Sep;
57(4):500-512.
PMID: 27669664
Oxycodone DETERx (Collegium Pharmaceutical Inc, Canton, Massachusetts) is an extended-release, microsphere-in-capsule, abuse-deterrent formulation designed to retain its extended-release properties after tampering (eg, chewing/crushing). This randomized, double-blind, placebo-controlled, triple-dummy study evaluated...
16.
McCarberg B, Kopecky E, OConnor M, Marseilles A, Varanasi R, Thompson C, et al.
Curr Med Res Opin
. 2016 Sep;
32(12):1975-1982.
PMID: 27668546
Background: Patients with chronic pain may experience difficulty swallowing, in part due to worsening disease, comorbid conditions, iatrogenic etiology, or age. Patients or caregivers may manipulate extended-release (ER) opioid formulations...
17.
Smith S, Gewandter J, Kitt R, Markman J, Vaughan J, Cowan P, et al.
J Pain
. 2016 Aug;
17(11):1198-1206.
PMID: 27555429
Perspective: This article presents the preferences of individuals with chronic pain conditions regarding modifiable pain treatment trial characteristics (eg, number of study visits, payment, treatment allocation). These findings may help...
18.
Edwards R, Dworkin R, Turk D, Angst M, Dionne R, Freeman R, et al.
Pain
. 2016 May;
157(9):1851-1871.
PMID: 27152687
There is tremendous interpatient variability in the response to analgesic therapy (even for efficacious treatments), which can be the source of great frustration in clinical practice. This has led to...
19.
Smith S, Amtmann D, Askew R, Gewandter J, Hunsinger M, Jensen M, et al.
Pain
. 2016 Apr;
157(5):1056-1064.
PMID: 27058680
Clinical trial participants often require additional instruction to prevent idiosyncratic interpretations regarding completion of patient-reported outcomes. The Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private...
20.
Taylor A, Phillips K, Patel K, Turk D, Dworkin R, Beaton D, et al.
Pain
. 2016 Apr;
157(9):1836-1850.
PMID: 27058676
Although pain reduction is commonly the primary outcome in chronic pain clinical trials, physical functioning is also important. A challenge in designing chronic pain trials to determine efficacy and effectiveness...